Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12) per share from the same period last year. The company reported quarterly sales of $28.624 million which beat the analyst consensus estimate of $17.382 million by 64.68 percent. This is a 57.13 percent decrease over sales of $66.769 million the same period last year.